Medicine and Dentistry
Clear Cell Renal Cell Carcinoma
100%
Clinical Trial
100%
Oncology
100%
Immunoglobulin
100%
Systematic Review
100%
Clinician
33%
Combination Therapy
33%
Malignant Neoplasm
16%
Overall Survival
16%
Progression Free Survival
16%
Randomized Clinical Trial
16%
Sunitinib
16%
Immune Checkpoint Inhibitor
16%
Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Phase III Clinical Trial
100%
Immuno-oncology
100%
Clinical Outcomes
33%
Combination Therapy
33%
Search Criteria
33%
Overall Survival
16%
Progression-free Survival
16%
Clinical Trials
16%
Data Extraction
16%
Randomized Clinical Trial
16%
Literature Search
16%
Treatment Recommendations
16%
PubMed
16%
Sunitinib
16%
Unique Characteristics
16%
PRISMA Guidelines
16%
Immune Checkpoint Inhibitors
16%
Descriptive Review
16%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Clinical Trial
100%
Immunoglobulin
100%
Combination Therapy
33%
Malignant Neoplasm
16%
Overall Survival
16%
Progression Free Survival
16%
Randomized Clinical Trial
16%
Sunitinib
16%
Immune Checkpoint Inhibitor
16%